Noticias de TEVA_US

Mercado

Noticias del mercado

Últimas noticias sobre TEVA_US — 466 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: TEVA_US ✕ 466 resultados
03/09/2026 TEVA_US — Moomoo
Goldman Sachs Initiates Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Announces Target Price $50
03/09/2026 TEVA_US — Moomoo
Jefferies Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $40
03/09/2026 TEVA_US — Yahoo Finance
Outperforming Pharma Stock Still Has Upside Potential
03/09/2026 TEVA_US — Moomoo
Scotiabank Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $40
02/09/2026 TEVA_US — GuruFocus
A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 3.6% G
02/09/2026 TEVA_US — Fierce Biotech
Teva autoimmune antibody notches ph. 2 win in celiac disease
02/09/2026 TEVA_US — Benzinga
Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study
02/09/2026 TEVA_US — Benzinga
Teva Stock Rises After TEV '408 Meets Primary Endpoint in Celiac Disease Study
02/09/2026 TEVA_US — whbl.com
Teva’s immune disorder drug meets main goal in mid-stage trial
02/09/2026 TEVA_US — WTVB
Teva’s immune disorder drug meets main goal in mid-stage trial

Sept 2 (Reuters) - Israeli drugmaker Teva Pharmaceutical Industries, said on Wednesday its experimental drug helped prevent gluten-related intestinal damage in adults with celiac disease, meeting the ​main goal of a mid-stage trial. U.S.-listed shares ...

02/09/2026 TEVA_US — The Pharma Letter
Teva's anti-IL-15 antibody hits primary endpoint in Phase IIa celiac disease study
02/09/2026 TEVA_US — Indian Pharma Post
Teva and Trump administration move toward deal to cut Medicaid drug costs
02/09/2026 TEVA_US — quiverquant.com
Teva Reports Positive Phase 2a Results for TEV ‘408 in Celiac Disease, Showing Statistically Significant Prevention of Gluten-Induced Intestinal Damage
02/09/2026 TEVA_US — Via Ritzau
Teva Pharmaceutical Industries Ltd
02/09/2026 TEVA_US — GlobeNewswire
Teva Announces Positive Topline Results from Phase 2a Study
02/09/2026 TEVA_US — Reuters
Teva's immune disorder drug meets main goal in mid-stage trial
02/09/2026 TEVA_US — Yahoo Finance
Teva's immune disorder drug meets main goal in mid-stage trial
02/09/2026 TEVA_US — Yahoo Finance
Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study
02/09/2026 TEVA_US — GlobeNewswire
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
02/09/2026 TEVA_US — Yahoo Finance
Teva Pharmaceutical Reports Positive Topline Data for Anti-IL-15 Drug in Celiac Disease

Página 12 de 24